{
  "docId": "019de06f-52ef-7226-b4e8-f3f08eb88a26",
  "docSlug": "7c032e01619eda769cbeaf2bcfe382bc",
  "documentTitle": "Pershing Square | Activist Presentation Deck | 110 slides",
  "authorId": "pershing-square",
  "authorName": "Pershing Square Capital Management",
  "documentKindSlug": "activist-deck",
  "documentKindLabel": "Activist deck",
  "sourceTypeSlug": "activist_investor",
  "sourceTypeLabel": "Activist investor",
  "presentationDate": "2014-04-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.3333334,
  "pageNumber": 36,
  "pageCount": 110,
  "prevPage": 35,
  "nextPage": 37,
  "slideType": "key_takeaways",
  "function": "summarize",
  "density": "sparse",
  "nDataPoints": 1,
  "notes": null,
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de06f-52ef-7226-b4e8-f3f08eb88a26/36",
  "deckHref": "/decks/019de06f-52ef-7226-b4e8-f3f08eb88a26",
  "deckJsonHref": "/decks/019de06f-52ef-7226-b4e8-f3f08eb88a26.json",
  "deckAnchorHref": "/decks/019de06f-52ef-7226-b4e8-f3f08eb88a26#slide-36",
  "components": [
    {
      "bbox": {
        "h": 0.7,
        "w": 0.7,
        "x": 0.04,
        "y": 0.18
      },
      "kind": "list",
      "text": "Line extensions and re-formulations\nExample: Acanya\nNew indications and strengths for existing drugs\nExample: Retin-A Micro .08%\nNew branded generics\nExample: 300 new product launches expected in 2014\nPrescription to OTC switches\nExample: Bedoyecta\nHigh-probability development programs (Phase IIIs)\nExample: Luzu\nLow-risk New Chemical Entities (NCE's)\nExample: Jublia",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "6167ebb3-2d0b-4aad-963f-8fa135942cce",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.05,
        "w": 0.6,
        "x": 0.04,
        "y": 0.06
      },
      "kind": "title",
      "text": "Track Record of R&D Productivity",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "20ee9dc3-79da-459f-8fa8-c95c9a880860",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [
    {
      "name": "List presentation",
      "slug": "list-presentation",
      "agent": null,
      "layer": "slide",
      "matchId": "1b9c78ac-74a5-4f18-b2d1-0e6c4b8783c6",
      "evidence": "list/bullet: Line extensions and re-formulations Example: Acanya New indications and strengths for existing drugs Example: Retin-A Micro .08% New branded generics Example: 300 new product launches expected in 2014 Prescr",
      "confidence": 0.9
    }
  ],
  "frameworks": [],
  "arcBeats": [],
  "loops": [],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}